| アブストラクト | BACKGROUND: Current methods for estimating the timeliness of cancer diagnosis are not robust because dates of key defining milestones, for example first presentation, are uncertain. This is exacerbated when patients have other conditions (multimorbidity), particularly those that share symptoms with cancer. Methods independent of this uncertainty are needed for accurate estimates of the timeliness of cancer diagnosis, and to understand how multimorbidity impacts the diagnostic process. METHODS: Participants were diagnosed with oesophagogastric cancer between 2010 and 2019. Controls were matched on year of birth, sex, general practice and multimorbidity burden calculated using the Cambridge Multimorbidity Score. Primary care data (Clinical Practice Research Datalink) was used to explore population-level consultation rates for up to two years before diagnosis across different multimorbidity burdens. Five approaches were compared on the timing of the consultation frequency increase, the inflection point for different multimorbidity burdens, different aggregated time-periods and sample sizes. RESULTS: We included 15,410 participants, of which 13,328 (86.5 %) had a measurable multimorbidity burden. Our new maximum likelihood estimation method found evidence that the inflection point in consultation frequency varied with multimorbidity burden, from 154 days (95 %CI 131.8-176.2) before diagnosis for patients with no multimorbidity, to 126 days (108.5-143.5) for patients with the greatest multimorbidity burden. Inflection points identified using alternative methods were closer to diagnosis for up to three burden groups. Sample size reduction and changing the aggregation period resulted in inflection points closer to diagnosis, with the smallest change for the maximum likelihood method. DISCUSSION: Existing methods to identify changes in consultation rates can introduce substantial bias which depends on sample size and aggregation period. The direct maximum likelihood method was less prone to this bias than other methods and offers a robust, population-level alternative for estimating the timeliness of cancer diagnosis. |
|---|
| ジャーナル名 | Cancer epidemiology |
|---|
| Pubmed追加日 | 2022/12/13 |
|---|
| 投稿者 | Price, Sarah; Wiering, Bianca; Mounce, Luke T A; Hamilton, Willie; Abel, Gary |
|---|
| 組織名 | Medical School, College of Medicine and Health, University of Exeter, St Luke's;Campus, Heavitree Road, Exeter EX1 2LU, UK.;Campus, Heavitree Road, Exeter EX1 2LU, UK. Electronic address:;b.wiering@exeter.ac.uk. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36508967/ |
|---|
